A practical compliance guide for pharmaceutical manufacturers, importers, distributors and drug registration holders
Thailand has replaced its 2023 technical framework for renewing drug registration certificates with a new evidence-based regime that applies from 16 July 2026. The change makes renewal a substantive reassessment of the product’s continuing quality, efficacy, safety and benefit-risk profile, rather than a routine administrative extension.
| Key Takeaways
• The 2026 Thai FDA notification took effect on 16 July 2026 and repeals the notification dated 28 September 2023. • The annex divides registrations into two renewal tracks; companies should classify each product before deciding what evidence to assemble. • A complete filing must connect quality, efficacy, safety, stability, labeling and risk-management evidence to the live registration. • The statutory 120-day review period begins only after the application is complete and the prescribed review charges and fees have been paid. • Pending applications are treated under the 2026 notification, so open files should be rechecked rather than assumed to be grandfathered. |
Figure 1. Effective date, transition rule and the two drug-registration renewal tracks.
Why the New Notification Matters
On 15 July 2026, the Thai Food and Drug Administration (Thai FDA) published a notification prescribing the documents or evidence required to demonstrate the quality, efficacy and safety of a drug when renewing its registration certificate, together with the criteria and conditions for evaluating that evidence. The notification was signed on 3 July 2026 and took effect on the day following publication, 16 July 2026. It expressly repeals the corresponding Thai FDA notification dated 28 September 2023.
The notification does not replace the Ministerial Regulation on Renewal of Drug Registration Certificates B.E. 2566 (2023). Instead, it performs the technical functions assigned to the Thai FDA Secretary-General under clauses 3(3) and 7, paragraph two, of that regulation: it identifies the quality, efficacy and safety evidence that must accompany a renewal application and explains the substantive standard against which that evidence will be assessed.
Accordingly, the new notification should be read together with the 2023 Ministerial Regulation, the applicable application form, Thai FDA checklists, product-specific orders and current electronic filing instructions. The regulation requires the registration holder to file within one year before the certificate expires. The general renewal file also includes the registration-certificate number, the relevant manufacturing or import license number, labels and package inserts, published patent or petty-patent application numbers where applicable and, when importing, a current foreign-manufacturing GMP certificate.
Two Renewal Tracks
The 2026 annex divides renewal dossiers into two categories. This classification is operationally important because it determines whether the applicant must assemble the more detailed evidence package in Annex 1 or may rely on the updated approved registration dossier contemplated by Annex 2.
✓ Track 1: legacy and special renewals. This track covers modern human and veterinary registrations issued from 1 January 1967 through 13 October 2019 and renewed under the transitional regime, transferred registrations that are not aligned with ASEAN or ICH registration guidance, and traditional veterinary drug registrations.
✓ Track 2: recurring seven-year renewals. This track covers modern human drug registrations aligned with ASEAN or ICH registration guidance and modern veterinary registrations aligned with the current veterinary registration manual. These registrations are renewed every seven years under section 86/2 of the Drug Act.
The notification further states that a registration renewed under one category must remain in that category for later renewals. Companies should therefore preserve the classification rationale and supporting record as part of the permanent regulatory file.
Renewal Is a Substantive Evidence Review
For both tracks, the Thai FDA considers the totality of the quality, efficacy and safety evidence together with any risk-management plan and implementation undertakings. Renewal may be granted where the product remains consistent with current scientific principles, is not disqualified under section 83 of the Drug Act, and continues to present a favorable benefit-risk balance.
The quality standard is equally important. Compendial specifications and analytical methods should follow the pharmacopeias recognized under Thai law. Where the product or method is noncompendial, the applicant must provide scientifically supportable specifications and analytical evidence demonstrating quality, efficacy and safety. For Track 2 human drugs, the quality package may consist of the ASEAN- or ICH-aligned dossier originally approved by the Thai FDA, updated to reflect all approved variations. This is not permission to rely on an outdated dossier: the file must still accurately represent the approved product as manufactured and marketed at renewal.
The annex also contains category-specific rules for modern veterinary and traditional veterinary medicines. Although the principles are similar, veterinary products require additional attention to recognized veterinary regulators, maximum residue limits or tolerances for food-producing animals, and the applicable veterinary registration manual.
Figure 2. The evidence architecture for a defensible drug-registration renewal.
The Evidence Package for Modern Human Drugs
1. Administrative and Product Consistency
The Thai FDA’s current human-drug checklist starts with a complete administrative and product record. The renewal application generated through SKYNET should correctly identify the registration holder; finished-product manufacturer; primary and secondary packagers; batch-release party; product name; dosage form; strength; pack sizes; immediate-contact packaging; composition; storage conditions; and applicable legal classification. The applicant should also confirm that the manufacturing or import license and, for imported products, the foreign-manufacturing GMP certificate remain valid.
Consistency across systems is a recurring implementation theme. The Thai FDA checklist instructs applicants to upload the same labeling and package-insert versions to DocuBridge and the relevant SKYNET record. A mismatch among the renewal form, approved variations, quality module, labels, PIL, SmPC or live manufacturing arrangements can create a completeness issue or expose an unfiled variation.
2. Quality and Manufacturing Evidence
For a detailed Track 1 dossier, the active pharmaceutical ingredient file should include complete specifications, test methods and acceptance criteria. The Thai FDA materials call for a certificate of analysis for one batch from the API manufacturer and from the finished-product manufacturer; where several API sources are registered, the evidence should cover every source.
The finished-product package should address the complete composition, reconstitution diluent where applicable, container-closure system, batch formula, overages and yields, manufacturing flow, process controls, critical steps, intermediate controls and sterile processing where relevant. It should also include excipient controls, finished-product specifications, a finished-product certificate of analysis, analytical procedures and validation data for in-house methods. For noncompendial products, the notification points human chemical drugs to ICH Q6A and human biological products to ICH Q6B.
Formulation changes should not be folded casually into renewal. The annex allows only necessary adjustments involving non-active ingredients, supported by evidence that the ingredient and proposed level are safe. Any broader change should be analyzed under the applicable variation pathway before the renewal file is finalized.
3. Stability Evidence
Stability is likely to be one of the most resource-intensive workstreams for legacy portfolios. The 2026 framework differentiates among several evidence scenarios:
✓ Where ASEAN- or ICH-compliant stability data already support the approved shelf life, the previously approved data may be submitted in updated form.
✓ Where shelf-life-supporting data are aligned with ASEAN or ICH but accelerated data are absent, ongoing or annual stability data may be used: at least two batches for a stable product and at least three batches for an unstable product or critical dosage form.
✓ Where stability evidence has been submitted but is not aligned with ASEAN or ICH, the same two- or three-batch approach may be used, together with a risk-management undertaking to complete the study through the shelf life and report within the committed timetable.
✓ Where no stability data have been filed, or the data do not cover the approved shelf life, the applicant should provide the study protocol, six months of accelerated data, at least six months of long-term data, and an undertaking to continue and report the study through the shelf life. Thai FDA FAQ material additionally indicates a tentative two-year shelf life for this scenario.
✓ A product needed for public health that cannot satisfy the ordinary stability package may be considered case by case, provided the applicant explains the necessity. This is a narrow regulatory discretion, not a general waiver.
4. Efficacy and Safety Evidence
For modern human drugs, the notification recognizes three principal routes for supporting efficacy and safety:
✓ A current SmPC for a product approved through the WHO prequalification program or by one of the notification’s listed stringent regulatory authorities. The active ingredient, dosage form and strength must match. The listed authorities include the EU/EMA, US FDA, Japan’s MHLW/PMDA, Swissmedic, Health Canada, Australia’s TGA, the Icelandic Medicines Agency, Liechtenstein, the Norwegian Medicines Agency and the UK MHRA.
✓ Evidence that the product appears in Thailand’s National List of Essential Medicines or the applicable household-remedy list.
✓ Research reports or scientific literature supporting efficacy or safety where neither of the first two routes is available.
Matching an SRA or WHO-prequalified product may reduce the need for additional clinical evidence only where the relevant particulars align and the Thai registration has no identified quality, efficacy or safety concern. Differences in dosage form, strength, indication, dose or method of administration require additional support. Track 2 new drugs and biological products must also include post-marketing safety information from use in Thailand, which may draw on the registration holder’s adverse-event database and data from Thailand or the World Health Organization.
5. Risk Management, Labeling and Commitments
Products with identified quality, efficacy or safety concerns may require a risk-management plan and an express undertaking to implement it. The Thai FDA checklist distinguishes products with identified concerns from those without such concerns and directs applicants to complete the Risk Management Plan section in SKYNET. The renewal team should verify whether product-specific risk-minimization measures or Ministry of Public Health orders apply.
Labels, PILs and SmPCs should be treated as controlled components of the renewal dossier, not as a late-stage publishing exercise. Thai FDA materials currently permit specified temporary arrangements for legacy inserts, supported by RMP commitments and a subsequent variation filing, generally no later than 13 April 2027. That relief must be applied carefully because product-specific warning, classification or amendment orders may impose an earlier date.
Processing Periods and Incomplete Documentation
The 2023 Ministerial Regulation establishes a two-stage process. First, the Thai FDA screens the application and supporting evidence for correctness and completeness. A defect that can be corrected immediately may be cured at the point of review. Otherwise, the authority records the deficiency and sets a period for the applicant to correct the application or submit the missing information.
If the applicant does not cure the recorded defects, provide complete supporting evidence, or pay the prescribed review charges and fees within the period set by the authority, the applicant is deemed not to wish to proceed. The Thai FDA may return the application and supporting materials, issue a written explanation and remove the matter from the docket. This consequence makes document readiness and payment governance central to continuity planning.
Only when the file is correct and complete and the charges and fees have been paid does the 120-day substantive review period begin. If renewal is approved, the authority must notify the applicant and issue the renewed certificate within seven days of the approval order. If renewal is refused, the applicant must receive the reasons and information on appeal rights within seven days.
Thai FDA FAQ guidance confirms that, where an application is filed within the permitted period and the required charges and fees are paid, the registration remains effective pending the renewal decision, including for importation, until an order refusing renewal is made.
Figure 3. Statutory renewal process, review period and consequences of an uncured deficiency.
Transitional Applications
Clause 5 of the 2026 notification addresses applications submitted before 16 July 2026 that remain under consideration. Those applications are treated as applications under the new notification, mutatis mutandis. In practical terms, a pending application should not be assumed to remain governed exclusively by the 2023 technical criteria.
Registration holders with open renewal files should promptly map the existing submission against the 2026 annex and current Thai FDA checklist, identify any changed or newly explicit expectations, and prepare supplemental evidence before a formal deficiency request is issued. Particular attention should be given to stability scenarios, current SRA or WHO reference documents, Thai post-marketing safety data for new drugs and biological products, RMP commitments, and consistency among approved variations, labels and electronic-system records.
Compliance Checklist
| Workstream | Required Action |
| Portfolio governance | List every registration certificate, holder, product, site, expiry date and responsible dossier owner; assign the correct renewal track. |
| Regulatory baseline | Reconcile the original approval, all approved variations, current licenses, foreign GMP evidence, labels, PIL, SmPC and published patent or petty-patent application numbers. |
| Quality dossier | Confirm current API and excipient specifications, COAs, batch formula, manufacturing process, finished-product specifications, analytical methods and validation. |
| Stability | Classify the evidence scenario; verify batch count, dosage-form risk, protocol, approved shelf life, commitments and reporting calendar. |
| Efficacy and safety | Select and document the applicable evidence route; identify differences from the reference product; assemble Thai post-marketing safety evidence where required. |
| Risk and labeling | Check product-specific concerns and orders; finalize the RMP, risk-minimization measures, PIL, SmPC and label implementation plan. |
| Electronic submission | Ensure that SKYNET, DocuBridge and the signed renewal file contain the same controlled versions and complete product particulars. |
| Deficiency response | Pre-authorize a cross-functional response team, evidence repository, translator access, payment owner and escalation route for Thai FDA deadlines. |
| Post-renewal control | Track every undertaking, follow-up study, label transition, report and variation as an auditable post-approval commitment. |
A Practical Renewal Timeline
The statutory filing window opens one year before expiry, but many portfolios should begin preparation earlier. Stability work, foreign-manufacturer data collection, analytical validation, label redevelopment and remediation of unfiled changes can take longer than the filing window. For high-volume portfolios, an 18-month readiness cycle is a reasonable governance target: map and classify first, perform the dossier gap assessment, commission missing evidence, integrate safety and labeling, and then file with a dedicated response and payment protocol.
Figure 4. Recommended portfolio-level readiness roadmap before the statutory filing window.
Our Take
The 2026 notification confirms that drug-registration renewal in Thailand is now an evidence-maintenance exercise across the product life cycle. The companies best positioned to manage it will be those that maintain a single source of truth linking the approved registration to current manufacturing practice, stability data, pharmacovigilance, labeling and change control. Treating renewal as an isolated filing project creates avoidable risk; treating it as portfolio governance supports continuity of supply and a more defensible regulatory record.
How MPG Can Assist
Mahanakorn Partners Group advises pharmaceutical manufacturers, importers, distributors and registration holders on Thai FDA strategy, regulatory due diligence, dossier and contract review, foreign-manufacturer coordination, licensing, variation planning, risk-management commitments, labeling and responses to regulatory deficiencies. We can also support portfolio-level renewal readiness reviews that combine Thai legal analysis with practical documentation and project governance.
This update is provided for general informational purposes only and does not constitute legal, regulatory, scientific or professional advice. The application of the rules depends on the product, registration history, dossier category and current Thai FDA practice. Businesses should obtain advice before taking action.